Skip to main content
InMed Pharmaceuticals Inc. (INM)
Nov 6, 2026 - INM was delisted (reason: merged into MTRI)
15.56
+2.35 (17.79%)
Inactive · Last trade price on Nov 6, 2026

InMed Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Market Capitalization
10742310
Market Cap Growth
113.11%76.38%65.69%-23.20%-68.00%-62.36%
Enterprise Value
920-4-65
Last Close Price
15.5615.5032.5053.10185.302352.00

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
PS Ratio
---0.520.758.85
PB Ratio
-6.440.290.260.261.06
P/TBV Ratio
-6.440.330.320.301.38

EV Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
EV/Sales Ratio
-----4.24

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Debt / Equity Ratio
--0.060.110.030.09
Net Debt / Equity Ratio
0.95-2.08-0.75-0.61-0.71-0.60
Net Debt / EBITDA Ratio
0.120.231.220.711.050.41
Net Debt / FCF Ratio
0.140.261.240.811.150.35
Asset Turnover
---0.360.310.10
Inventory Turnover
---2.441.33-
Quick Ratio
0.451.145.863.534.611.90
Current Ratio
0.501.376.994.415.662.89
Return on Equity (ROE)
-222.07%-156.77%-76.77%-72.08%-75.09%-226.07%
Return on Assets (ROA)
-85.56%-66.46%-38.53%-39.22%-38.94%-75.28%
Return on Capital Employed (ROCE)
837.00%-920.50%-61.50%-82.60%-69.20%-143.60%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Earnings Yield
-192.37%-181.52%-208.04%-324.14%-257.76%-193.02%
FCF Yield
-75.98%-124.91%-206.44%-295.41%-241.46%-162.13%
Buyback Yield / Dilution
-151.03%-326.64%-156.11%-211.26%--
SEC Filings: 10-K · 10-Q